Business Wire

PA-PHLEXGLOBAL

Share
Phlexglobal, the TMF Experts, announces key appointments.

Phlexglobal, pioneers in the provision of Trial Master File (TMF) technology and services for the global life sciences industry announces the appointment of three experienced industry professionals to its senior teams.

John Loucks joins as chief commercial officer, bringing to Phlexglobal over 15 years of executive leadership, management and life science industry experience from companies including Oracle and SAS. Most recently John was head of health sciences solutions at EMC Corporation, where he significantly increased sales and substantially increased EMC’s market share. In his new role, John will lead Phlexglobal’s global sales and marketing teams, responsible for all business development activities across its widespread client base.

John commented “I am excited to be joining a successful team with such a strong reputation as the TMF experts in the industry. I look forward to working with the sales and marketing teams and being part of the company’s continued growth and worldwide expansion plans.”

Client Solutions, led by senior vice president Karen Roy, is expanding with the addition of two key members, Marion Mays and Richard Shore. The goal of client solutions is to help companies improve their business practices and workflows to achieve excellence in the administration and management of all their documentation and data.

Marion has a wealth of experience leveraging the competitive advantage of managing records and the TMF in an audit-ready manner, having steered the development and implementation of regulated, enterprise-wide programs across organizations including Wyeth and Pfizer. Marion was previously at Quintiles for 5 years, where she led global records management operations, quality teams, and worked directly with customers to support initiatives. A widely respected leader in the information management community, Marion is a strong advocate for essential information management practices. She understands how to bridge legacy systems and processes with new approaches which fully leverage the abilities of the new technologies and systems.

Richard has over 20 years’ pharmaceutical IT systems experience, predominantly with GSK. Experienced in ensuring that IT systems are compliant with industry standards and regulatory requirements, Richard has vital knowledge on the development and validation of eTMF systems. Most recently Richard was a technical subject matter expert at Biogen, where he was the lead for their project to integrate its eTMF with a strategic partner CRO system.

Marion and Richard’s considerable experience will expand the range of expertise-driven, consultative services Phlexglobal provides, and build on its position as the industry’s leading TMF thought leaders and experts.

Rick Riegel, Phlexglobal CEO, commented “Phlexglobal continues to grow rapidly as we build upon our industry position as the TMF experts and industry leaders. We are very excited to have John, Marion and Richard join our team as we also continue to broaden the management depth and expertise of our global team.”

About Phlexglobal

Phlexglobal is a specialist provider of both industry leading eTMF technology solutions and expert TMF & eTMF technology-enabled services. Offering a unique combination of clinical trial knowledge, document management skills, regulatory understanding and technical expertise, we deliver a range of flexible, targeted solutions to meet business needs.

More information can be found at: http://www.phlexglobal.com

-Ends-

Contact:

Phlexglobal Ltd
Gillian Gittens, head of marketing
Tel: +44(0)1494 720420

Social Media:

https://www.facebook.com/phlexglobal

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release

Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin

Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 202525.4.2025 14:00:00 CEST | Press release

Incyte (Nasdaq:INCY) today announced that the Company will present new early-stage data from its oncology portfolio at the American Association of Cancer Research (AACR) Annual Meeting 2025 in Chicago, IL, from April 25–30. “At AACR we will be presenting data from early-stage programs across our oncology portfolio, including for patients with myeloproliferative neoplasms, ovarian cancer and other solid tumors,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “These data will guide our approach as we advance our pipeline and seek to transform the treatment landscape for patients with cancer and myeloproliferative neoplasms.” Abstracts accepted for presentation at AACR include: Mini Symposium INCB177054 INCB177054: A Novel, Potent, Orally Bioavailable DGKα/ζ Dual Inhibitor Enhances T-Cell Function and Demonstrates Potent Antitumor Activity (Session Title: Novel Antitumor Agents. April 28, 4:50 p.m. – 5:05 p.m. ET (3:50 p.m. – 4:05 p.m. CT). Abstract #

SLB Announces First-Quarter 2025 Results; Remains Committed to Return a Minimum of $4 Billion to Shareholders in 202525.4.2025 12:50:00 CEST | Press release

Revenue of $8.49 billion decreased 3% year on year GAAP EPS of $0.58 decreased 22% year on year EPS, excluding charges and credits, of $0.72 decreased 4% year on year Net income attributable to SLB of $797 million decreased 25% year on year Adjusted EBITDA of $2.02 billion decreased 2% year on year Cash flow from operations of $660 million increased $333 million year on year Board approved quarterly cash dividend of $0.285 per share SLB (NYSE: SLB) today announced results for the first-quarter 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250423635499/en/ The exterior of the SLB headquarters in Houston, Texas. First-Quarter Results (Stated in millions, except per share amounts) Three Months EndedChange Mar. 31, 2025 Dec. 31, 2024 Mar. 31, 2024 Sequential Year-on-year Revenue $8,490 $9,284 $8,707 -9% -3% Income before taxes - GAAP basis $1,063 $1,387 $1,357 -23% -22% Income before taxes margin - GAAP basis 12.5% 14.9%

Corona, The World’s Most Valuable Beer Brand1, Announces Its 100-Year Anniversary with Global Celebration25.4.2025 10:00:00 CEST | Press release

Brand Invites The World to Join the Celebration with Experiences at the Most Epic Beaches on EarthGlobal “Corona 100” Platform Launches with a Legendary Concert at Copacabana Beach, Featuring One of the World’s Top Musical Artists with Millions in Attendance Today, Corona proudly celebrates its 100-year anniversary, a remarkable milestone for the iconic brand that has been synonymous with the beach and enjoyed by consumers worldwide for the past century. Since 1925, Corona has cultivated a deep association with the beach; fully embodying a lifestyle connected to nature and relaxation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425804516/en/ Corona 100 This Is Living Since 1925 In honor of the occasion, Corona invites everyone to live their “beach side” – a.k.a. their best side – at top-tier beach locations across the globe. The Corona 100 platform includes a film highlighting 100 years of beach culture, a definitive l

Ant Group Unveils New Recruitment Initiative for Top AI Talents, Ramping Up AI Innovation Efforts25.4.2025 09:28:00 CEST | Press release

Ant Group today unveiled Plan A, a new recruitment initiative to attract top artificial intelligence researchers, reinforcing its commitment to accelerating AI research and development under the “AI First” corporate strategy. Operating within the framework of Ant Star—Ant Group’s year-round campus recruitment program—Plan A specifically targets AI talents who are ambitious, adaptable, altruistic, and analytical. Outstanding graduates from universities worldwide with STEM majors are encouraged to apply for Plan A. Relevant fields include computer science, software engineering, artificial intelligence, cybersecurity, information and telecommunication engineering, mathematics, statistics, and other emerging interdisciplinary areas. To better foster the development of technological innovators in this new AI era, Plan A offers candidates comprehensive support and resources, including unrestricted access to AI hardware and tailored career paths that allow for significant research freedom. Ad

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye